BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence

Use of BPC-157, an unapproved synthetic peptide nicknamed the "Wolverine" peptide for its purported healing and performance-enhancing effects, rose 33-fold in documented cases between 2020 and 2026, according to a new analysis.¹

Confirmed Use Climbed as the Patient Population Shifted Younger and More Male

The peptide, marketed directly to consumers for pain relief, tissue healing, and performance enhancement, has not been approved by the FDA for any indication. Because BPC-157 carries no National Drug Code, researchers at data analytics firm nference searched more than 15 million medical records for mentions of the compound and used large language models, validated by physician review, to confirm actual use in clinical notes.

Of 1536 patients whose notes mentioned BPC-157, 1039 had documented use, and the number of newly confirmed users rose from 4 in the first quarter of 2020 to 134 in the first quarter of 2026—a roughly 33-fold increase. The demographic profile of users also shifted: the male share climbed from 57% in 2020 to 70% in 2026, while the mean age fell from 55 to 49.² Among the 972 users with documented race, 96% were White.

Gray-Market Sourcing and Drug Stacking Were Common

A specific reason for use was documented in 644 patients. Pain was the most common indication, cited by 33% of the patients, followed by gastrointestinal conditions such as reflux, inflammatory bowel disease, or gastritis in 14%, prior injury in 11%, and post-surgical healing in 10%.¹

Among the 205 users with a documented supply source, most obtained BPC-157 through a compounding pharmacy (36%) or a gray-market peptide vendor (35%). Just over half of all confirmed users also took at least one other therapeutic agent alongside BPC-157, most often testosterone, nonsteroidal anti-inflammatory drugs, the peptide TB-500—its partner in the so-called "Wolverine stack"—or corticosteroids.

Outcomes Remain Largely Unproven Amid an Ongoing FDA Compounding Debate

Only 354 of the 1039 confirmed users had a documented directional response to treatment, and 79% of those reported improvement. Study leader Venky Soundararajan, PhD, cautioned that most physicians are not systematically asking patients about BPC-157 use, so the true scope of use is likely undercounted.² Flynn McGuire, MD, of the University of Utah, who studies BPC-157 but was not involved in the analysis, noted that roughly half of the documented users were also taking other drugs or undergoing interventions such as physical therapy or surgery, and that the study lacked a placebo or untreated comparison group, a standardized dose or formulation, or consistent outcome measurement—making it impossible to attribute any reported improvement specifically to BPC-157.

When discontinuation was documented, clinician advice was the most common reason followed by adverse events; reported effects included neuropsychiatric, dermatologic, and gastrointestinal symptoms. The FDA's Adverse Event Reporting System has logged 10 serious adverse event reports tied to BPC-157 since 2021, 8 of them in 2026 alone, though the agency notes such reports do not establish causation.

The findings arrive as the FDA weighs whether to permit pharmacy compounding of BPC-157, a shift an FDA advisory panel endorsed in July with HHS Secretary Robert F. Kennedy Jr's encouragement,³ though the agency had previously restricted compounding over safety concerns and has not yet issued a final decision.

References

1. Venkatakrishnan AJ, Marwaha A, Gregg CJ, et al. Rising use of unapproved BPC-157 ("Wolverine peptide") and associated patient-reported outcomes curated from clinical notes. Preprints.org. Published online September 7, 2026. doi:10.20944/preprints202609.0501.v1
2. Lapid N. Use of untested 'Wolverine' peptide backed by US Health Secretary Kennedy on the rise, study finds. Reuters. September 15, 2026. Accessed September 17, 2026. https://www.reuters.com/legal/litigation/use-untested-wolverine-peptide-backed-by-us-health-secretary-kennedy-rise-study-2026-09-15/
3. Steinzor P. FDA panel backs 6 peptides for compounding. AJMC^®. July 31, 2026. Accessed September 18, 2026. https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding